Agents in late-stage development for the treatment of Crohn's disease, ulcerative colitis, irritable bowel syndrome, and short bowel syndrome
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Lilly’s Oral GLP-1 Meets Endpoints in Phase 3 Trial
Read More
Employers: Cancer, GLP-1 Drugs and Mental Health Driving Healthcare Costs
FDA Approves First in Class Therapy for Hereditary Angioedema
MedImpact To Offer Unbranded Ustekinumab-aekn Biosimilar
FDA Set Review Date for Imcivree for Rare Form of Obesity
Medicare Patients Face Higher Drug Costs Despite $2,000 Spending Cap